Delivery Order SPE2DR25D6028-SPE2DR26FASEX
- Not listed
- The Defense Logistics Agency awarded a $26,705.50 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is...
- The Defense Logistics Agency awarded a $10,892.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an ultimate completion date of November 4, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on October 27, 2025, with completion targeted for October 28, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX). The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $6,558.40. Issued on November 14, 2025, with an ultimate completion date of November 17, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $50,518.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 20, 2025, with an ultimate completion date of June 23, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a $28,730.55 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $87,792.14. This firm fixed-price delivery order, awarded on July 23, 2025, represents a non-set-aside competitive award with an ultimate completion date of July 24, 2025. The pharmaceutical products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and...
- The Defense Logistics Agency awarded a $26,987.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for supply of RINVOQ ER 15 mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of December 1, 2025. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $40,365.01 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 13, 2025, with an ultimate completion date of November 14, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate...
- SPE2DR25D6028Indefinite Delivery Contract
- SPE2DR25D6028-SPE2DR26FASEXDelivery Order
The Defense Logistics Agency awarded a $49,188.15 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15MG tablets (30-count units) under contract number 4570137441. The contract was competitively awarded without set-aside designation and is scheduled for completion by December 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performing location for this delivery order, leveraging its established role as a critical pharmaceutical distributor for federal medical procurement. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. RINVOQ (upadacitinib) is a Janus kinase inhibitor used for rheumatoid arthritis and other autoimmune conditions, reflecting the scope of specialty medications provided through this vehicle to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $49.2k | 12/1/25 |